Progress in understanding the structure-activity relationships of P-glycoprotein

Advanced Drug Delivery Reviews

Volumn 54, Issue 3, 2002, Pages 315-328

  Stouch, Terry R ^a   Gudmundsson, Olafur ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b GENENTECH INC   (United States)

Author keywords

MDR, multiple drug resistance; Molecular modeling; P glycoprotein, P gp; SAR, structure activity relationships

Indexed keywords

ASSAYS; BINDING ENERGY; GLYCOLS; STRUCTURE (COMPOSITION); SUBSTRATES;

ANTI-CANCER DRUGS; BIOAVAILABILITY;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; COLCHICINE; CYCLOSPORIN; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DILTIAZEM; DOCETAXEL; ESTRADIOL; FELODIPINE; GLYCOPROTEIN P; HYDROCORTISONE; INDINAVIR; ITRACONAZOLE; MITHRAMYCIN; MITOMYCIN; MORPHINE; PACLITAXEL; POLYSORBATE 80; PROGESTERONE; PUROMYCIN; RAPAMYCIN; SAQUINAVIR; SOLUTOL HS 15; TESTOSTERONE; TOPOTECAN; TRITON X 100; VERAPAMIL; VINBLASTINE; VINCRISTINE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ASSAY; BINDING SITE; BIOAVAILABILITY; CARBOXY TERMINAL SEQUENCE; CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; LIPOPHILICITY; MOLECULAR MODEL; MOLECULAR SIZE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 0037204543     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00006-6     Document Type: Article

References (71)

1. Biochemical, cellular and pharmacological aspects of the multidrug transporter
2. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
3. P-glycoprotein - A mediator of multidrug resistance in tumor cells
4. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
5. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein
6. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
7. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
8. In vivo model systems in P-glycoprotein-mediated multidrug resistance
9. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
10. P-Glycoprotein, a gatekeeper in the blood-brain barrier
11. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone
12. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid
13. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
14. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine
15. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
16. New triazine derivatives as potent modulators of multidrug resistance
17. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines
18. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance
19. New purines and purine analogs as modulators of multidrug resistance
20. Photoaffinity substrates for P-glycoprotein
21. Characterization of multidrug resistance by fluorescent dyes
22. A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells
23. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein
24. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells
25. A biophysical model of passive and polarized active transport processes in Caco-2 cells: Approaches to uncoupling apical and basolateral membrane events in the intact cell
26. Drug-stimulated ATPase activity of the human P-glycoprotein
27. Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity
28. P-glycoprotein substrates and antagonists cluster into two distinct groups
29. Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis
30. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells
31. The effects of lipids and detergents on ATPase-active P-glycoprotein
32. Progress in predicting human ADME parameters in silico
33. How does P-glycoprotein recognize its substrates?
34. Structure-activity relationship of multidrug resistance reversers
35. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities
36. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
37. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site
38. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
39. Expression of an mdr gene is associated with a new form of resistance to dexamethasone - Induces apoptosis
40. A general pattern for substrate recognition by P-glycoprotein
41. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein
42. The Importance of a nitrogen atom in modulators of multidrug resistance
43. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein
44. Structure-activity relationship of P-glycoprotein substrates and modifiers
45. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics
46. Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/log P and ACD/ChemSketch descriptors
47. Quantitative structure-activity relationship of multidrug resistance reversal agents
48. Reversal of multidrug resistance by phenothiazines and structurally related compounds
49. Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds
50. Pharmacokinetics and metabolism in early drug discovery
51. Communication between multiple drug binding sites on P-glycoprotein
52. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells
53. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study
54. A Comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance
55. Flavonoid-related modulators of multidrug resistance: Synthesis, pharmacological activity, and structure-activity relationships
56. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells
57. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line
58. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
59. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine
60. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein
61. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents
62. Derivatives of a novel cyclopeptolide. 2. Synthesis, activity against multidrug resistance in CHO and KB cells in vitro, and structure-activity relationships
63. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines
64. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells
65. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance
66. Reversal of multidrug resistance by derivatives of acrivastine: A study of structure-activity relationships of P-glycoprotein inhibitors in vitro and in vivo
67. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer
68. Characterization of binding properties to human P-glycoprotein: Development of a [3H]verapamil radioligand-binding assay
69. Novel multidrug resistance reversal agents
70. Chemistry and biological activity of new 3-benzazepines